跳至主要内容
临床试验/NL-OMON50502
NL-OMON50502已完成3 期

A randomized placebo-controlled study in patients with a Gallium-68 DOTATATE PET/CT positive, clinically non-functioning pituitary macroadenoma (NFMA) of the effect of Lanreotide autosolution on Tumor (adenoma) size - GALANT

Academisch Medisch Centrum0 个研究点目标入组 66 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
66

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • * Clinically non-functioning pituitary macroadenoma, or post-surgical
  • residue/recurrence ><= 10mm, with suprasellar extension

排除标准

  • * Optic chiasm compression and/or visual field defects
  • * Hypersensitivity for somatostatin or similar peptides
  • * Obstructive neuroendocrine gut tumor
  • * Symptomatic cholelithiasis
  • * Use of dopamine agonists in the past 6 months
  • * Use of somatostatin analogues in the past 6 months
  • * Pregnancy (plans)
  • * Any contraindication to perform MRI with gadolinium based contrast agent
  • (including implanted metallic devices, impaired renal function and severe
  • claustrophobia)

研究者

相似试验

A randomized placebo-controlled study in patients... | 临床试验